DrugDashboards

Bupivacaine Hydrochloride

Bupivacaine hydrochloride · BUPIVACAINE HYDROCHLORIDE 7.5 mg/mL · Injection · Subarachnoid · Huons Co., Ltd.

NDC 73293-0002-02 · 50 AMPULE in 1 PACKAGE / 2 mL in 1 AMPULE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. It is in shortage right now — FDA lists the reason as “demand increase for the drug”. A Class II recall hit this product in the past year (Huons Co., Ltd.). One of its named manufacturing plants, Huons Co., Ltd., failed FDA inspectionwithin the last two years — the agency’s most serious outcome.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.6%chance of a new FDA shortage posting for bupivacaine hydrochloride (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA212822
TE code
AP
Approval date
Dec 30, 2019
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)Feb 20, 2018
    Demand increase for the drug
    month 103 — 5× the typical 20-month injectable shortage · model puts 15% odds it resolves within 6 months

Recalls (this NDC)

  • Class II · OngoingApr 2, 2026
    Huons Co., Ltd. — Lack of Assurance of Sterility

Manufacturers of Bupivacaine hydrochloride (Injection)

LabelerStrengthFirst seenLast seen
Brookfield Pharmaceuticals, LLC.BUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 2, 2026
Huons Co., Ltd.BUPIVACAINE HYDROCHLORIDE 7.5 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Bupivacaine Hydrochloride — NDC 73293-0002-02," retrieved September 3, 2026, https://drugdashboards.com/drug/73293000202.

Free to cite with attribution — see how the data is put together.